Larry Bock has aided in starting or financing 40 early stage growth company, that combined have a market value of more than $30 billion. He received a degree in biochemestry and has a M.B.A, after school he worked for Genentech. Bock is a donor, co-found, and the executive director of USA Science and Engineering Festival. Bock was highlighted as a keystone species to the ecosystem of Silicon Valley in the book The Rainforest. A keystone species in the innovation context is someone who connects people who would benefit working together, however would not work together under normal circumstance because of trust, distance, and/or cultural barriers. Bock has invested in several companies including: Acceleron Pharma, Aurora Biosciences, Biosym Technologies, ekoVenture, Gen-Probe a blood screening company, Gensia Pharmaceuticals, Genocea Biosciences, IDEC Pharmaceuticals Magen Biosciences, Oclassen Pharmaceuticals: commercialized Cinoxacin, Plexikon Pharmaceuticals, Poland Partners, Sequana Therapeutics, Sapphire Energy produces crude oil from algae, Siluria, Sirtris Pharmaceuticals therapies for type 2 diabetes and types of cancer, Software Transformation, and Viagene. Bock has been a CEO of Nanosys, where he helped to raise $55 million in funding. Bock was also a special limited partner with Lux Capital.Bock has founded the following companies: Illumina a biotechnology company for genetic products, Nanosys a nanotechnology company for optics and batteries, Pharmacopeia biotechnology a company investigating small molecule combinatorial chemistry, Idun Pharmaceuticals company developing drugs targeting apoptosis, and Caliper Life Sciences to aid in drug discovery.
$950,000
